NCT07596186

Brief Summary

The study will recruit 100 participants aged 65+ residing in assisted living facilities. Eligible participants will undergo an initial cognitive assessment to document their baseline cognitive status using cognitive tests conducted either in their assisted living facility or at Soroka Medical Center. An app designed for research data collection (Aware-Light) will be installed on participants' mobile devices, collecting data only after participants provide consent. Over three months, the app will automatically gather sensor data, including movement data from the accelerometer, orientation data from the gravity sensor, rotation data from the gyroscope, proximity data for measuring distance from nearby objects, ambient light levels from the light sensor, and typing dynamics such as typing frequency and duration without recording actual text. The app will also track app usage, including activation, pauses, closures, background activity, notifications, and crashes, as well as air pressure through the barometer, phone capabilities through the telephony detector, and screen states such as on, locked, or off. It will log communication events such as calls and messages without recording personal details, monitor vehicle speed through the linear accelerometer, track rotation angles through the rotation detector, and identify significant movements like walking, cycling, or traveling. No typed data, such as passwords, will be collected. After one month, the research team will contact participants to ensure the app functions correctly. After three months, participants will undergo a second cognitive assessment, and the app will be uninstalled.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Dec 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Dec 2024Jan 2027

Study Start

First participant enrolled

December 1, 2024

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

May 13, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 19, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2027

Last Updated

May 19, 2026

Status Verified

May 1, 2026

Enrollment Period

2.1 years

First QC Date

May 13, 2026

Last Update Submit

May 13, 2026

Conditions

Keywords

Early DementiaMild Cognitive Decline

Outcome Measures

Primary Outcomes (1)

  • Prediction model of mobile device data, collected for 9 months of lower scores in Neurotrax cognitive assessment compared to baseline evaluation.

    Mobile device sensor data

    Baseline and 9 Month after

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Tenants in assisted living housing

You may qualify if:

  • Age 65 and over
  • Clalit HMO members.
  • Without a known diagnosis of dementia
  • Uses Android mobile phones and writes text messages

You may not qualify if:

  • A known diagnosis of dementia
  • Uses IOS mobile.
  • Doesn't write text messages

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Soroka Medical Center

Beersheba, Israel

Location

MeSH Terms

Conditions

Cognitive DysfunctionLymphoma, FollicularDementia

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Gal Ifergane, MD-MHA

    Soroka University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Neurology Department

Study Record Dates

First Submitted

May 13, 2026

First Posted

May 19, 2026

Study Start

December 1, 2024

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Last Updated

May 19, 2026

Record last verified: 2026-05

Locations